Tyler Flaningham
Psychiatry · Carmel, INNPI 1538369053
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 450 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,912 and has fallen 56.6% since, to $829 in 2025. Among psychiatry clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 450 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Supernus Pharmaceuticals, Inc.$846
- Ironshore Pharmaceuticals Inc.$605
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$440
- Vanda Pharmaceuticals Inc.$391
- Neurocrine Biosciences, Inc.$368
- plus $3K from 24 others
What the payments were for
- Food & beverage$7,372100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 71 | $1,563 |
| Supernus Pharmaceuticals, Inc. | 134 | $846 |
| Ironshore Pharmaceuticals Inc. | 29 | $605 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $440 |
| Vanda Pharmaceuticals Inc. | 17 | $391 |
| Neurocrine Biosciences, Inc. | 12 | $368 |
| Johnson & Johnson | 19 | $364 |
| Teva Pharmaceuticals USA, Inc. | 19 | $360 |
| Otsuka America Pharmaceutical, Inc. | 8 | $320 |
| Alkermes, Inc. | 13 | $281 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $231 |
| Bausch Health US, LLC | 15 | $219 |
| Lundbeck LLC | 15 | $185 |
| Axsome Therapeutics, Inc. | 7 | $148 |
| Arbor Pharmaceuticals, Inc. | 1 | $140 |
| Neos Therapeutics, LP | 8 | $135 |
| Corium, LLC | 10 | $128 |
| Collegium Pharmaceutical, Inc. | 5 | $102 |
| Vertical Pharmaceuticals, LLC | 5 | $99 |
| Jazz Pharmaceuticals Inc. | 4 | $93 |
| Shire North American Group Inc | 5 | $73 |
| Orexo US, Inc. | 5 | $72 |
| Avanir Pharmaceuticals, Inc. | 2 | $41 |
| Tris Pharma Inc | 3 | $41 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
| Tonix Medicines, Inc. | 1 | $24 |
| Indivior Inc. | 2 | $24 |
| Nalpropion Pharmaceuticals LLC | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $18 |
| Eisai Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,372 in reported general payments places this provider in the 90th percentile of 514 psychiatry providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 47 | $12,688 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 19 | $9,498 |
| Buprenorphine Hcl | 23 | $2,016 |
| Lurasidone Hcl | 18 | $1,525 |
| Oxcarbazepine | 14 | $1,127 |
| Lamotrigine | 38 | $579 |
| Bupropion XlBupropion Hcl | 25 | $516 |
| Risperidone | 33 | $414 |
| Clonazepam | 31 | $409 |
| Trazodone Hcl | 21 | $369 |
| Fluoxetine Hcl | 21 | $352 |
| Duloxetine Hcl | 13 | $352 |
| Gabapentin | 21 | $309 |
| Zolpidem Tartrate | 29 | $168 |
| Buspirone Hcl | 17 | $129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Suboxone | $24 | $9,49819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Carmel
- Steven PaulCarmel$2.9M
- Christopher BojrabCarmel$713K
- Michael DetkeCarmel$14K
- Michael WebberCarmel$9K
- Jay FawverAngola$1.4M
- Suhayl NasrMichigan City$739K
- Joseph FanelliMunster$443K
- Eric JaggersJeffersonville$260K
- Larry LambertsonFort Wayne$208K
- Louis CadyNewburgh$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.